{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:49:02Z","timestamp":1790952542587,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This research was partially supported by a grant from NextCure Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures. Pharmaceutical therapies that promote anabolic bone formation in OP patients and OP-induced fracture are needed. We investigated whether a neutralizing antibody against Siglec-15 can simultaneously inhibit bone resorption and stimulate bone formation. We found that the multinucleation of osteoclasts was inhibited in <jats:italic>SIGLEC-15<\/jats:italic> conditional knockout mice and mice undergoing Siglec-15 neutralizing antibody treatment. The secretion of platelet-derived growth factor-BB (PDGF-BB), the number of tartrate-resistant acid phosphatase-positive (TRAP<jats:sup>+<\/jats:sup>) mononuclear cells, and bone formation were significantly increased in the <jats:italic>SIGLEC-15<\/jats:italic> conditional knockout mice and antibody-treated mice. The anabolic effect of the Siglec-15 neutralizing antibody on bone formation was blunted in mice with <jats:italic>Pdgfb<\/jats:italic> deleted in TRAP<jats:sup>+<\/jats:sup> cells. These findings showed that the anabolic effect of the Siglec-15 neutralizing antibody was mediated by elevating PDGF-BB production of TRAP<jats:sup>+<\/jats:sup> mononuclear cells. To test the therapeutic potential of the Siglec-15 neutralizing antibody, we injected the antibody in an ovariectomy-induced osteoporotic mouse model, which mimics postmenopausal osteoporosis in women, and in two fracture healing models because fracture is the most serious health consequence of osteoporosis. The Siglec-15 neutralizing antibody effectively reduced bone resorption and stimulated bone formation in estrogen deficiency-induced osteoporosis. Of note, the Siglec-15 neutralizing antibody promoted intramembranous and endochondral ossification at the damaged area of cortical bone in fracture healing mouse models. Thus, the Siglec-15 neutralizing antibody shows significant translational potential as a novel therapy for OP and bone fracture.<\/jats:p>","DOI":"10.1038\/s41413-021-00161-1","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T03:02:24Z","timestamp":1635735744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-6226","authenticated-orcid":false,"given":"Gehua","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda N.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengwu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"161_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255\u2013266 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"161_CR2","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1002\/jbmr.1989","volume":"28","author":"Y Kameda","year":"2013","unstructured":"Kameda, Y. et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase\/Akt and Erk pathways in association with signaling Adaptor DAP12. J. Bone Miner. Res. 28, 2463\u20132475 (2013).","journal-title":"J. Bone Miner. Res"},{"key":"161_CR3","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.1074\/jbc.M113.494542","volume":"289","author":"M Stuible","year":"2014","unstructured":"Stuible, M. et al. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J. Biol. Chem. 289, 6498\u20136512 (2014).","journal-title":"J. Biol. Chem."},{"key":"161_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bone.2014.10.027","volume":"71","author":"Y Kameda","year":"2015","unstructured":"Kameda, Y. et al. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Bone 71, 217\u2013226 (2015).","journal-title":"Bone"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"17493","DOI":"10.1074\/jbc.M111.324194","volume":"287","author":"N Ishida-Kitagawa","year":"2012","unstructured":"Ishida-Kitagawa, N. et al. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12kD (DAP12). J. Biol. Chem. 287, 17493\u201317502 (2012).","journal-title":"J. Biol. Chem."},{"key":"161_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1359\/JBMR.0301234","volume":"19","author":"MB Humphrey","year":"2004","unstructured":"Humphrey, M. B. et al. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 19, 224\u2013234 (2004).","journal-title":"J. Bone Miner. Res"},{"key":"161_CR7","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright, N. C. et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J. Bone Miner. Res. 29, 2520\u20132526 (2014).","journal-title":"J. Bone Miner. Res"},{"key":"161_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel, K. A. & Drake, M. T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin. Proc. 84, 632\u2013637 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"161_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","volume":"86","author":"B Abrahamsen","year":"2010","unstructured":"Abrahamsen, B. Adverse effects of bisphosphonates. Calcif. Tissue Int. 86, 421\u2013435 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"161_CR10","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1002\/jcp.26587","volume":"233","author":"N Ding","year":"2018","unstructured":"Ding, N. et al. Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress. J. Cell Physiol. 233, 7415\u20137423 (2018).","journal-title":"J. Cell Physiol."},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts, N. B. & Diab, D. L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555\u20131565 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"161_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2174\/1381612013397780","volume":"7","author":"P Morley","year":"2001","unstructured":"Morley, P., Whitfield, J. F. & Willick, G. E. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr. Pharm. Des. 7, 671\u2013687 (2001).","journal-title":"Curr. Pharm. Des."},{"key":"161_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1503\/cmaj.050929","volume":"175","author":"A Cranney","year":"2006","unstructured":"Cranney, A. et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 175, 52\u201359 (2006).","journal-title":"CMAJ"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis, A. D., Polyzos, S. A. & Makras, P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31\u2013R45 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"161_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"Khosla, S. & Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5, 898\u2013907 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"161_CR16","first-page":"62","volume":"2","author":"BZ Leder","year":"2018","unstructured":"Leder, B. Z. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. J. Bone Miner. Res. 2, 62\u201368 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","volume":"30","author":"S Lou","year":"2019","unstructured":"Lou, S. et al. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos. Int. 30, 59\u201370 (2019).","journal-title":"Osteoporos. Int."},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"e26267","DOI":"10.1371\/journal.pone.0026267","volume":"6","author":"L Shen","year":"2011","unstructured":"Shen, L. et al. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One 6, e26267 (2011).","journal-title":"PLoS One"},{"key":"161_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1759720X18805759","volume":"10","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki, E. M. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis. 10, 209\u2013223 (2018).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"161_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337\u2013342 (2003).","journal-title":"Nature"},{"key":"161_CR21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/nm.3668","volume":"20","author":"H Xie","year":"2014","unstructured":"Xie, H. et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 20, 1270\u20131278 (2014).","journal-title":"Nat. Med."},{"key":"161_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature13145","volume":"507","author":"AP Kusumbe","year":"2014","unstructured":"Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323\u2013328 (2014).","journal-title":"Nature"},{"key":"161_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature13146","volume":"507","author":"SK Ramasamy","year":"2014","unstructured":"Ramasamy, S. K., Kusumbe, A. P., Wang, L. & Adams, R. H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 507, 376\u2013380 (2014).","journal-title":"Nature"},{"key":"161_CR24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1210\/endo.143.5.8813","volume":"143","author":"P Boissy","year":"2002","unstructured":"Boissy, P., Saltel, F., Bouniol, C., Jurdic, P. & Machuca-Gayet, I. Transcriptional activity of nuclei in multinucleated osteoclasts and its modulation by calcitonin. Endocrinology 143, 1913\u20131921 (2002).","journal-title":"Endocrinology"},{"key":"161_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature02444","volume":"428","author":"T Koga","year":"2004","unstructured":"Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758\u2013763 (2004).","journal-title":"Nature"},{"key":"161_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1476-5381.2008.00095.x","volume":"156","author":"CH Chung","year":"2009","unstructured":"Chung, C. H., Lin, K. T., Chang, C. H., Peng, H. C. & Huang, T. F. The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production. Br. J. Pharm. 156, 846\u2013856 (2009).","journal-title":"Br. J. Pharm."},{"key":"161_CR27","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/sj.onc.1208516","volume":"24","author":"PY Au","year":"2005","unstructured":"Au, P. Y. et al. The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene 24, 3196\u20133205 (2005).","journal-title":"Oncogene"},{"key":"161_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.3987","volume":"35","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Glucocorticoids disrupt skeletal angiogenesis through transrepression of NF-kappaB-mediated preosteoclast Pdgfb transcription in young mice. J. Bone Min. Res. 35, 1188\u20131202 (2020).","journal-title":"J. Bone Min. Res."},{"key":"161_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/nm1514","volume":"12","author":"SH Lee","year":"2006","unstructured":"Lee, S. H. et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med. 12, 1403\u20131409 (2006).","journal-title":"Nat. Med."},{"key":"161_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00223-019-00573-6","volume":"105","author":"L Rochette","year":"2019","unstructured":"Rochette, L. et al. The role of osteoprotegerin in vascular calcification and bone metabolism: the basis for developing new therapeutics. Calcif. Tissue Int. 105, 239\u2013251 (2019).","journal-title":"Calcif. Tissue Int."},{"key":"161_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.36","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Human type H vessels are a sensitive biomarker of bone mass. Cell Death Dis. 8, e2760 (2017).","journal-title":"Cell Death Dis."},{"key":"161_CR32","first-page":"1700578","volume":"5","author":"C Dou","year":"2018","unstructured":"Dou, C. et al. Graphene-based MicroRNA transfection blocks preosteoclast fusion to increase bone formation and vascularization. Adv. Sci. (Weinh.) 5, 1700578 (2018).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"161_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41591-018-0020-z","volume":"24","author":"R Xu","year":"2018","unstructured":"Xu, R. et al. Targeting skeletal endothelium to ameliorate bone loss. Nat. Med. 24, 823\u2013833 (2018).","journal-title":"Nat. Med."},{"key":"161_CR34","first-page":"1","volume":"13","author":"SK Stewart","year":"2019","unstructured":"Stewart, S. K. Fracture non-union: a review of clinical challenges and future research needs. Malays. Orthop. J. 13, 1\u201310 (2019).","journal-title":"Malays. Orthop. J."},{"key":"161_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.injury.2011.03.035","volume":"42","author":"KD Hankenson","year":"2011","unstructured":"Hankenson, K. D., Dishowitz, M., Gray, C. & Schenker, M. Angiogenesis in bone regeneration. Injury 42, 556\u2013561 (2011).","journal-title":"Injury"},{"key":"161_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cps.2016.11.005","volume":"44","author":"AD Deng","year":"2017","unstructured":"Deng, A. D., Innocenti, M., Arora, R., Gabl, M. & Tang, J. B. Vascularized small-bone transfers for fracture nonunion and bony defects. Clin. Plast. Surg. 44, 267\u2013285 (2017).","journal-title":"Clin. Plast. Surg."}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00161-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:38:56Z","timestamp":1669919936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-021-00161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1038\/s41413-021-00161-1","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"1 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}